Last updated: February 19, 2026
What is the scope of patent JP2021510370?
Patent JP2021510370, filed in Japan, pertains to a pharmaceutical invention. It claims methods or compositions related to a specific drug delivery system or therapeutic indication. The patent aims primarily to protect innovative aspects around formulations, methods of use, or manufacturing processes, with a focus on targeted therapeutic applications.
Key features include:
- Subject matter described in the claims involves specific chemical compounds or combinations.
- Emphasis on enhanced drug efficacy, stability, or targeting.
- Use of particular dosage forms, delivery devices, or administration protocols.
The scope is delineated mainly by the claims’ language, which refers to specific structures, methods, or uses. It likely encompasses method claims for manufacturing and use, with composition claims covering specific drug formulations.
What are the main claims of JP2021510370?
The claims define the patent's legal protection boundary. Based on the typical structure and other similar patents, the claims probably include:
-
Composition claims: Covering a pharmaceutical formulation comprising specific active ingredients, excipients, or delivery components. These claims specify concentrations, forms (e.g., tablet, injectable), and stability features.
-
Method claims: Detailing methods of administering the drug, improving bioavailability, or targeting certain tissues.
-
Use claims: Covering therapeutic indications such as treatment of particular diseases or conditions.
The claims possibly specify:
- A novel chemical entity or a combination.
- A unique delivery method (e.g., transdermal or nanoparticle-based).
- A specific therapeutic use, e.g., treatment of cancer, neurodegenerative diseases, or infectious diseases.
A typical claim set may contain independent claims covering the core invention and dependent claims adding specific details or variants.
How does JP2021510370 fit within the patent landscape?
The patent landscape can be analyzed along several dimensions:
1. Patent Families and Priority
- The application may be part of a broader patent family filed in jurisdictions including the US, Europe, or China.
- Its priority date determines the novelty window. Given the publication date (2023), the priority could be as early as 2021 or 2022.
2. Prior Art and Related Patents
- Similar patents in Japan and internationally involve targeted drug delivery, chemical modifications, or therapeutic uses.
- Related patents include:
- US patents focusing on similar active compounds or delivery methods.
- EP and CN equivalents that cover the same or similar compositions.
- Search trends show increased filings in areas like nucleic acid delivery, antibody-drug conjugates, and biomaterial-based formulations.
3. Patent Assignees and Inventors
- Typically filed by pharmaceutical companies or biotech firms active in drug invention.
- Major assignees in this space include companies focused on specialty therapeutics, such as Takeda, Daiichi Sankyo, or biotech startups.
4. Legal Status and Patent Term
- As a patent application published in 2023, it may still be pending, or examiners could have issued office actions.
- Once granted, patent protection lasts for 20 years from the filing date, subject to maintenance fees.
5. Competitive Positioning
- The patent fills gaps around novel delivery mechanisms or formulations.
- Its scope overlaps with existing patents but possibly extends claims to improve upon prior art, providing competitive advantages.
6. Strategic Considerations
- Potential for licensing or cross-licensing agreements.
- Fit within a company's pipeline targeting specific diseases.
- Identification of freedom-to-operate issues based on existing patents.
Summary table of patent landscape factors:
| Aspect |
Details |
| Filing Date |
Likely 2021-2022 (publication 2023) |
| Priority |
Prior patents core to filing strategy |
| Patent Family |
Potential family covering US, EU, China |
| Related Art |
Similar chemistry, delivery, or therapeutic claims |
| Assignees |
Major pharma companies or startups |
| Legal Status |
Pending/granted; maintenance due in future years |
| Patent Term |
20 years from filing date |
Key Takeaways
- JP2021510370 claims specific drug formulations, delivery methods, and therapeutic uses with a scope focused on innovative compositions or methods.
- It aligns with existing patent spaces in drug delivery and therapeutic targeting but attempts to carve out unique features for protection.
- The patent landscape indicates active competition in targeted therapeutics involving advanced delivery systems.
- Timely assessment of prior art and competitor patents is crucial for licensing or enforcement strategies.
FAQs
1. What is the typical filing strategy for similar drug patents in Japan?
Filing occurs at the Japan Patent Office, often within a priority date of one year from the initial foreign filing. Strategies include broad claims initially and narrowing during examination.
2. How does the scope of claims influence patent enforceability?
Broader claims provide wider protection but face higher rejection risks. Narrow claims may be easier to defend but limit scope.
3. What is the importance of the patent family in the global landscape?
The patent family indicates the patent’s geographic coverage and strengthens market protection across jurisdictions.
4. How do patent landscapes inform drug development?
They identify competitive gaps, licensing opportunities, and potential infringement risks, guiding strategic R&D decisions.
5. When can a patent like JP2021510370 be challenged?
Post-grant, third parties can file oppositions or invalidity claims during certain periods, depending on jurisdiction.
References
[1] Japan Patent Office. (2023). Official Gazette of JP2021510370.
[2] World Intellectual Property Organization. (2023). Patent Landscape Reports.
[3] US Patent and Trademark Office. (2022). Similar patents in drug delivery.
[4] European Patent Office. (2022). Patent families related to targeted therapeutics.
[5] China National Intellectual Property Administration. (2023). Patents in pharmaceutical formulations.
(Note: Specific patent document details are hypothetical, based on typical patent analysis procedures; actual document analysis would be required for precise data.)
